We are a Nevada corporation originally incorporated on March 20, 2007. From 2007 to early 2018, we operated under a number of different names with different management teams and in different industries. On March 21, 2018, we changed our name to Marizyme Inc. to reflect our new biomedical focus, and also changed our common stock ticker symbol to “MRZM.”

Today, we are a Company with a diversified group of medical technology platforms acquired through multiple strategic acquisitions. In the second half of 2018, we acquired the Krillase® technology platform from ACB Holding AB; in the second half of 2020, we acquired Somahlution LLC and its related companies, including our flagship product, DuraGraft®; and in December 2021, we acquired My Health Logic Inc. ("MHL") from Health Logic Interactive Inc. ("HLII"). In connection with our MHL acquisition, David Barthel, former Chief Executive Officer of HLII and MHL, became our Chief Executive Officer and a member of our board of directors; George Kovalyov, previously the Chief Operating Officer and a director of HLII, became our Chief Financial Officer.

With a strengthened leadership team and a new breadth of assets, Marizyme is ready to advance on its development and commercialization goals to deliver continued success and shareholder value. Led by our world-class management team, Marizyme seeks to leverage its full suite of biomedical technologies to dramatically improve patient outcomes for some of the world’s most prevalent and costly healthcare challenges, including coronary artery bypass graft (CABG) surgery, pet health, and chronic kidney disease (CKD). To address these large markets, Marizyme presents its product and technology pipeline of: DuraGraft®, Krillase®, and MATLOC, respectively.

With these first-in-class medical technologies Marizyme can improve outcomes for millions of patients worldwide. Please join us on our journey as we look to change the acute care landscape in several target industries.